NEW YORK (TheStreet) -- Nektar Therapeutics (NKTR - Get Report) shares are up 9.8% to $12.13.

The rise follows an initiation of coverage with a "buy" rating and $15 price target by analysts at Jefferies Group (JEF).

The positive rating comes on speculation about the approval of the drug manufacturer's once a day opiod-induced constipation relieving pill, Naloxegol, which Jefferies believes could provide a major boost to the company's bottom line.

The FDA panel reviewing the drug is set to meet in mid-June.

Must Read: Warren Buffett's 10 Favorite Stocks

SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more.

NKTR Chart

NKTR data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.